BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal...
BioCentury | Feb 6, 2018
Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

In a study published in Proceedings of the National Academy of Sciences , the co-founders of Ilya Pharma AB (Uppsala, Sweden) showed topical delivery of Lactobacillus reuteri engineered to express chemokine CXC motif ligand 12 (CXCL12;...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest agonizing TRPC6 could help treat AD. In hippocampal neurons from two mouse models of familial AD, overexpression of TRPC6 or two TRPC agonists increased the percentage of mushroom...
BioCentury | Nov 8, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Potassium channel KCa2.2 (KCNN2); KCNN3; ataxin 2 (ATXN2; SCA2) Mouse studies suggest positive allosteric modulators (PAMs) of KCNN2 could help treat spinocerebellar ataxia type...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Huntingtin (HTT); ataxin 3 (ATXN3) In vitro and mouse studies identified peptoids that bind polyglutamate repeats and could help treat HD. A...
BioCentury | Jul 30, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Ataxin 2 (ATXN2; SCA2) Studies in mice suggest that dantrolene could help treat spinocerebellar ataxia type 2, a neurodegenerative disease caused by polyglutamine expansion...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Inositol 1,4,5-triphosphate receptor (ITPR1; IP3R); huntingtin (HTT) In vitro and in vivo mouse studies suggest that an ITPR1-derived...
BioCentury | Feb 12, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/9 cls Achillion (ACHN) JMP Securities Adam Cutler Price target Market outperform -54% $8.87 Cutler lowered his target to $15...
BioCentury | Jan 22, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk cls 1/19 cls Actelion (SWX:ATLN) ING Bank Mark Clark New Sell 6% CHF273.5 Lehman Peter Welford Price target Overweight Clark set a CHF220 target. He...
Items per page:
1 - 10 of 16
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal...
BioCentury | Feb 6, 2018
Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

In a study published in Proceedings of the National Academy of Sciences , the co-founders of Ilya Pharma AB (Uppsala, Sweden) showed topical delivery of Lactobacillus reuteri engineered to express chemokine CXC motif ligand 12 (CXCL12;...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest agonizing TRPC6 could help treat AD. In hippocampal neurons from two mouse models of familial AD, overexpression of TRPC6 or two TRPC agonists increased the percentage of mushroom...
BioCentury | Nov 8, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Potassium channel KCa2.2 (KCNN2); KCNN3; ataxin 2 (ATXN2; SCA2) Mouse studies suggest positive allosteric modulators (PAMs) of KCNN2 could help treat spinocerebellar ataxia type...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Huntingtin (HTT); ataxin 3 (ATXN3) In vitro and mouse studies identified peptoids that bind polyglutamate repeats and could help treat HD. A...
BioCentury | Jul 30, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Ataxin 2 (ATXN2; SCA2) Studies in mice suggest that dantrolene could help treat spinocerebellar ataxia type 2, a neurodegenerative disease caused by polyglutamine expansion...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Inositol 1,4,5-triphosphate receptor (ITPR1; IP3R); huntingtin (HTT) In vitro and in vivo mouse studies suggest that an ITPR1-derived...
BioCentury | Feb 12, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/9 cls Achillion (ACHN) JMP Securities Adam Cutler Price target Market outperform -54% $8.87 Cutler lowered his target to $15...
BioCentury | Jan 22, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk cls 1/19 cls Actelion (SWX:ATLN) ING Bank Mark Clark New Sell 6% CHF273.5 Lehman Peter Welford Price target Overweight Clark set a CHF220 target. He...
Items per page:
1 - 10 of 16